Listening to Luddites: Innovation Antibodies and Corporate Success

Protracted innovation is an essential activity of every organization in the modern global marketplace and is fueled by a continuous stream of fresh ideas. Contemporary business literature decries the innovation antibody, employees who intentionally thwart the acquisition and dissemination of crucial new ideas. The business press posits but one uniform type of innovation antibody often unwittingly encouraged by corporate actions, and should be quickly and effectively neutralized. This paper asserts that, like biological antibodies in the human body, the work of innovation antibodies in the corporate body can be either positive or negative. It is true that recalcitrant negative innovation antibodies determined to slow or eliminate innovation must be excised from the organization. Positive innovation antibodies are important to organizational sensemaking and innovation activities, and should not be suppressed or overcome. A revised innovation sequencing model is put forth to guide the activities of positive innovation antibodies, as are specific actions recommended for organizations to encourage the appropriate growth and use of positive innovation antibodies to effect corporate innovation success.